아이큐어

175250KOSDAQ기타 화학제품 제조업

55.8 / 100

Reference Date: 2026-06-10

Financial Score10.0 / 40

News Sentiment18.8 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IQure, established in 2000, specializes in developing transdermal drug delivery systems (TDDS) and pharmaceutical patches, along with OEM/ODM cosmetics. Following the successful Phase III trial of its donepezil patch in 2021, the company has secured global licensing agreements with pharmaceutical giants like Menarini and Celltrion. It also operates an ISO-certified cosmetics manufacturing facility, focusing on skincare OEM/ODM.

Number of Employees

286people

Average Salary

10.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 16.504.0Point

PBR

3.33Industry Average 1.130.0Point

2.9x industry avg (risky)

ROE

-82.73Industry Average 4.550.0Point

Well below industry avg

Debt Ratio

30.72Industry Average 8.130.0Point

3.8x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲21.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲27.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.8% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 75

Positive
아이큐어, 소염진통제 '플렉센' UAE 품목허가 획득
아이큐어의 소염진통제 플루르비프로펜 플렉센이 UAE에서 품목허가를 획득하여 글로벌 시장 진출에 긍정적 영향 기대.
Negative
아이큐어, 알츠하이머 치료제 임상1상 시험 자진취하
아이큐어의 알츠하이머 치료제 임상 1상 시험 자진취하로 인해 기업의 사업성 저하 우려가 제기됨.

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 2,170Won52-week high 2,17052-week low 1,805

1-month return3.0Point

1m 0% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral투자판단관련주요경영사항(임상시험계획자진취하등) (도네페질패취의 미국 FDA 제1상 임상시험계획 자진취하)2026-05-22
Neutral분기보고서 (2026.03)2026-05-15
Neutral[기재정정]분기보고서 (2026.03)2026-05-15